Preclinical study reveals reduced tumor incidence and hepatoprotection with Saphia Alkali K90 in Swiss mice, suggesting potential anticancer activity.
The present study aimed to initially evaluate the anti-tumor effect of orally administered Saphia Alkali K90 in 7,12-dimethylbenz(a)anthracene (DMBA)-induced carcinogenesis in Swiss mice. Mice exposed to DMBA (total dose of 6 mg, p.o.) were treated with SAK90 at 15 ml/kg BW and 45 ml/kg BW daily. The vehicle was given to both normal and diseased controls. The change in body weight, mortality rate, tumor incidence, tumor burden, tumor yield, histopathology, and hematological and biochemical parameters were evaluated after 16 weeks of treatment. 23,26% of DMBA-exposed mice presented neoplasms. SAK90 tended to reduce death, tumor incidence, and tumor yield compared to the DMBA group. The formulation exhibited protective effects against DMBA-induced hepatotoxicity through a trend in drop transaminase levels and increased albumin concentration concurrently compared to the DMBA group. This study suggested that SAK90 has potential anticancer activity.
No takes yet. Share an insight, caveat, or question.
Anh et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: